SeekingAlphaAugust 12, 2026 at 11:22 AM NY23 days ago

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Aura Biosciences, Inc. update: Bel-sar Phase 3 trial enrolled; topline data due 2H 2027. Click for more on AURA stock.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha

Companies in This Story